Safety assessment of the dietary supplement OxyELITE™ Pro (New Formula) in inbred and outbred mouse strains

Food and Chemical Toxicology

Volumn 109, Issue , 2017, Pages 194-209

  Miousse, Isabelle R ^a   Skinner, Charles M ^a   Lin, Haixia ^a   Ewing, Laura E ^a,b   Kosanke, Stanley D ^c,d   Williams, D Keith ^b   Avula, Bharathi ^e   Khan, Ikhlas A ^e   ElSohly, Mahmoud A ^f   Gurley, Bill J ^a   Koturbash, Igor ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d Mulinlx Ogden Hall Andrews and Ludlam PLLC   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

^f ElSohly Laboratories   (United States)

Author keywords

Dietary supplements; Drug induced liver injury; Hepatotoxicity; Phytochemicals

Indexed keywords

MICRORNA; MICRORNA 125B; MICRORNA 192; MICRORNA 193A; UNCLASSIFIED DRUG;

ALDOA GENE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CCNG1 GENE; CD36 GENE; CONTROLLED STUDY; DIETARY SUPPLEMENT; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; LIVER TOXICITY; MALE; MOLECULAR DYNAMICS; MOUSE; MOUSE STRAIN; NONHUMAN; NQO1 GENE; PHYTOCHEMISTRY; PROTEIN DENATURATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCD1 GENE; TXNRD1 GENE; WEIGHT GAIN; WEIGHT REDUCTION; ANALYSIS; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; INBRED MOUSE STRAIN; LIVER; METABOLISM; ORGAN SIZE; OUTBRED STRAIN; PATHOPHYSIOLOGY; PRECLINICAL STUDY; TOXIC HEPATITIS; TOXICITY; TOXICITY TESTING;

ANIMALS; ANIMALS, OUTBRED STRAINS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LIVER; MALE; MICE; MICE, INBRED STRAINS; MICRORNAS; ORGAN SIZE; TOXICITY TESTS;

EID: 85028915149     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2017.08.025     Document Type: Article

References (84)

1. Albonico, S.M., Kuck, A.M., Deulofeu, V., Tembamide from Fagara hiemalis. J. Chem. Soc. C 14 (1967), 1327–1328.
2. Aleksunes, L.M., Goedken, M., Manautou, J.E., Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J. Gastroenterol. 12 (2006), 1937–1940.
3. Anonymous, Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Fed. Reg. 69 (2004), 6787–6854.
4. Arseculeratne, S.N., Gunatilaka, A.L., Panabokke, R.G., Studies on medicinal plants of Sri Lanka. Part 14: toxicity of some traditional medicinal herbs. J. Ethnopharmacol. 13 (1985), 323–335.
5. Avigan, M.I., Mozersky, R.P., Seeff, L.B., Scientific and Regulatory Perspectives in Herbal and dietary supplement associated hepatotoxicity in the United States. Int. J. Mol. Sci., 17, 2016, 105.
6. Bailey, R.L., Gahche, J.J., Lentino, C.V., Dwyer, J.T., Engel, J.S., Thomas, P.R., Betz, J.M., Sempos, C.T., Picciano, M.F., Dietary supplement use in the United States, 2003-2006. J. Nutr. 141 (2011), 261–266.
7. Bloomer, R., Schriefer, J., Gunnels, T., Clinical safety assessment of oral higenamine supplementation in healthy, young men. Hum. Exp. Toxicol. 34 (2015), 935–945.
8. Bonkovsky, H.L., Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann. Intern. Med. 144 (2006), 68–71.
9. Bras, G., Jelliffe, D.B., Stuart, K.L., Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. Ama Arch. Pathol. 57 (1954), 285–300.
10. Brewer, A.C., Mustafi, S.B., Murray, T.V.A., Rajasekaran, N.S., Benjamin, I.J., Reductive stress linked to small HSPs, G6PD, and Nrf2 pathways in heart disease. Antioxid. Redox Signal 18 (2013), 1114–1127.
11. Brown, N.J., Ryder, D., Branch, R.A., A pharmacodynamic inter- action between caffeine and phenylpropanolamine. Clin. Pharmacol. Ther. 50 (1991), 363–371.
12. Brown, C.E., Trauth, S.E., Grippo, R.S., Gurley, B.J., Grippo, A.A., Combined effects of ephedrine- containing dietary supplements, caf- feine, and nicotine on morphology and ultrastructure of rat hearts. J. Caffeine Res. 2 (2012), 123–132.
13. Calabrese, V., Cornelius, C., Dinkova-Kostova, A.T., Iavicoli, I., Di Paola, R., Koverech, A., Cuzzocrea, S., Rizzarelli, E., Calabrese, E.J., Cellular stress responses, hormetic phyto- chemicals and vitagenes in aging and longevity. Biochim. Biophys. Acta 1822 (2012), 753–783.
14. Chatham-Stephens, K., Taylor, E., Chang, A., Peterson, A., Daniel, J., Martin, C., Deuster, P., Noe, R., Kieszak, S., Schier, J., Klontz, K., Lewis, L., Hepatotoxicity associated with weight loss or sports dietary supplements, including OxyELITE Pro (TM) - United States, 2013. Drug Test. Anal. 9 (2017), 68–74.
15. Chen, J.H., Yu, G.F., Jin, S.Y., Zhang, W.H., Lei, D.X., Zhou, S.L., Song, X.R., Activation of alpha 2 adrenoceptor attenuates lipopolysaccharide-induced hepatic injury. Int. J. Clin. Exp. Pathol. 8 (2015), 10752–10759.
16. Chen, S., Zhang, Z., Qing, T., Ren, Z., Yu, D., Couch, L., Ning, B., Mei, N., Shi, L., Tolleson, W.H., Activation of the Nrf2 signaling pathway in usnic acid-induced toxicity in HepG2 cells. Arch. Toxicol. 91 (2017), 1293–1307.
17. Choi, Y.J., Lee, K.Y., Jung, S.H., Kim, H.S., Shim, G.Y., Kim, M.G., Oh, Y.K., Oh, S.H., Jun, D.W., Lee, B.H., Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice (vol 316, pg 74, 2017). Toxicol. Appl. Pharm., 320, 2017, 73.
18. Church, R.J., Gatti, D.M., Urban, T.J., Long, N., Yang, X., Shi, Q., Eaddy, J.S., Mosedale, M., Ballard, S., Churchill, G.A., Navarro, V., Watkins, P.B., Threadgill, D.W., Harrill, A.H., Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. Food Chem. Toxicol. 76 (2015), 19–26.
19. Daviet, L., McGregor, J.L., Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Thromb. Haemost. 78 (1997), 65–69.
20. de Boer, Y.S., Sherker, A.H., Herbal and dietary supplement-induced liver injury. Clin. Liver Dis., 21, 2017 135-+.
21. Derlet, R.W., Tseng, J.C., Albertson, T.E., Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am. J. Emerg. Med. 10 (1992), 211–216.
22. Dodson, M., Redmann, M., Rajasekaran, N.S., Darley-Usmar, V., Zhang, J., KEAP1-NRF2 signalling and autophagy in protection against oxidative and reductive proteotoxicity. Biochem. J. 469 (2015), 347–355.
23. Dunnick, J.K., Kissling, G., Gerken, D.K., Vallant, M.A., Nyska, A., Cardiotoxicity of Ma Huang/caffeine or ephedrine/caffeine in a rodent model system. Toxicol. Path 35 (2007), 657–664.
24. Foley, S., Butlin, E., Shields, W., Lacey, B., Experience with OxyELITE pro and acute liver injury in active duty service members. Dig. Dis. Sci. 59 (2014), 3117–3121.
25. Fong, T.L., Klontz, K.C., Canas-Coto, A., Casper, S.J., Durazo, F.A., Davern, T.J., Hayashi, P., Lee, W.M., Seeff, L.B., Hepatotoxicity due to Hydroxycut: a case series. Am. J. Gastroenterol. 105 (2010), 1561–1566.
26. Gurley, B.J., Pharmacokinetic herb-drug interactions (Part 1): origins, mechanisms, and the impact of botanical dietary supplements. Planta Med. 78 (2012), 1478–1489.
27. Gurley, B.J., Steelman, S.C., Thomas, S.L., Multi-ingredient, caffeine-containing dietary supplements: history, safety, and efficacy. Clin. Ther. 37 (2015), 275–301.
28. Gurley, B.J., Markowitz, J.S., Williams, D.K., Barone, G.W., Practical considerations when designing and conducting clinical pharmacokinetic herb–drug interaction studies. Int. J. Pharmacokinet. 2 (2017), 57–69.
29. Haller, C.A., Peyton, J., Benowitz, N.L., Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin. Pharmacol. Ther. 75 (2004), 259–273.
30. Heidemann, L.A., Navarro, V.J., Ahmad, J., Hayashi, P.H., Stolz, A., Kleiner, D.E., Fontana, R.J., Severe acute hepatocellular injury attributed to OxyELITE Pro: a case series. Dig. Dis. Sci. 61 (2016), 2741–2748.
31. Heise, T., Schmidt, F., Knebel, C., Rieke, S., Haider, W., Pfeil, R., Kneuer, C., Niemann, L., Marx-Stoelting, P., Hepatotoxic effects of (tri)azole fungicides in a broad dose range. Arch. Toxicol. 89 (2015), 2105–2117.
32. Ingelman-Sundberg, M., Genetic polymorphism of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5 (2005), 6–13.
33. Johnston, D.I., Chang, A., Viray, M., Chatham-Stephens, K., He, H., Taylor, E., Wong, L.L., Schier, J., Martin, C., Fabricant, D., Salter, M., Lewis, L., Park, S.Y., Hepatotoxicity associated with the dietary supplement OxyELITE Pro (TM) Hawaii, 2013. Drug Test. Anal. 8 (2016), 319–327.
34. Kamal, A., Shaik, A.A., Sandbhor, M., Malik, M.S., Chemoenzymatic synthesis of (R)- and (S)-tembamide, aegeline and denopamine by a one-pot lipase resolution protocol. Tetrahedron Asymmetry 15 (2004), 3939–3944.
35. Kanda, T., Yokosuka, O., Okada, O., Suzuki, Y., Saisho, H., Severe hepatotoxicity associated with Chinese diet product ‘Onshidou-Genbi-Kounou’. J. Gastroenterol. Hepatol. 18 (2003), 354–355.
36. Kearney, T., Tu, N., Haller, C., Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann. Pharmacother. 44 (2010), 1022–1029.
37. Khan, T.H., Sultana, S., Antioxidant and hepatoprotective potential of Aegle marmelos Correa. against CCl4-induced oxidative stress and early tumor events. J. Enzym. Inhib. Med. Ch 24 (2009), 320–327.
38. Koturbash, I., Scherhag, A., Sorrentino, J., Sexton, K., Bodnar, W., Swenberg, J.A., Beland, F.A., de Villena, F.P.M., Rusyn, I., Pogribny, I.P., Epigenetic mechanisms of mouse interstrain variability in genotoxicity of the environmental toxicant 1,3-butadiene. Toxicol. Sci. 122 (2011), 448–456.
39. Koturbash, I., Beland, F.A., Pogribny, I.P., Role of microRNAs in the regulation of drug metabolizing genes and the response to environmental toxicants. Expert Opin. Drug Metab. Toxicol. 8 (2012), 597–606.
40. Koturbash, I., Tolleson, W., Guo, L., Yu, D., Chen, S., Hong, H., Mattes, W., Ning, B., MicroRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. Biomark. Med. 9 (2015), 1153–1176.
41. 2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin. Pharmacol. Ther. 76 (2004), 139–153.
42. Lee, J.H., Wada, T., Febbraio, M., He, J.H., Matsubara, T., Lee, M.J., Gonzalez, F.J., Xie, W., A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139 (2010), 653–663.
43. Lee, S.R., Schriefer, J.M., Gunnels, T.A., Harvey, I.C., Bloomer, R.J., Acute oral intake of a higenamine-based dietary supplement increases circulating free fatty acids and energy expenditure in human subjects. Lipids Health Dis., 12, 2013, 148.
44. Lei, X.G., Zhu, J.-H., Cheng, W.-H., Bao, Y., Ho, Y.-S., Reddi, A.R., Holmgren, A., Arnér, E.S.J., Paradoxical roles of antioxidant enzymes: basic mechanisms and health implications. Physiol. Rev. 96 (2016), 307–364.
45. Liu, Y., Santillo, M.F., CYtochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements. Drug Test. Anal. 8 (2016), 307–310.
46. Liu, J., Lu, Y.-F., Zhang, Y., Wu, K.C., Fan, F., Klaassen, C.D., Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in mice. Toxicol. Appl. Pharmacol. 272 (2013), 816–824.
47. Liu, Q.Y., Lei, Z.X., Huang, A.X., Wu, Q.H., Xie, S.Y., Awais, I., Dai, M.H., Wang, X., Yuan, Z.H., Toxic metabolites, MAPK and Nrf2/Keap1 signaling pathways involved in oxidative toxicity in mice liver after chronic exposure to Mequindox. Sci. Rep-Uk, 7, 2017.
48. Lo, C.F., Chen, C.M., Acute toxicity of higenamine in mice. Planta Med. 63 (1997), 95–96.
49. Manda, V.K., Avula, B., Chittiboyina, A.G., Khan, I.A., Walker, L.A., Khan, S.I., Inhibition of CYP3A4 and CYP1A2 by Aegle marmelos and its constituents. Xenobiotica 46 (2016), 117–125.
50. Manda, V., Avula, B., Mir, T.M., Ashfaq, M.K., Khan, I.A., Khan, S.I., Pharmacokinetics of aegeline after oral administration in a mouse model. Poster Presentation, International Conference on the Science of Botanicals, 2017 Oxford, MS, April 4-7, 2017 http://www.oxfordicsb.org/images/PDF/17th/2017_ICSB_Poster_Abstracts.pdf.
51. McNamara, R., Aoife, K., O'Neill, B., Harkin, A., Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (‘‘Ecstasy’’) and MDA (‘‘Love’’). Neuropharmacology 50 (2006), 69–80.
52. Minami, K., Saito, T., Narahara, M., Tomita, H., Kato, H., Sugiyama, H., Katoh, M., Nakajima, M., Yokoi, T., Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol. Sci. 87 (2005), 296–305.
53. Miousse, I.R., Murphy, L.A., Lin, H., Schisler, M.R., Sun, J., Chalbot, M.C., Sura, R., Johnson, K., LeBaron, M.J., Kavouras, I.G., Schnackenberg, L.K., Beger, R.D., Rasoulpour, R.J., Koturbash, I., Dose-response analysis of epigenetic, metabolic, and apical endpoints after short-term exposure to experimental hepatotoxicants. Food Chem. Toxicol. 17 (2017), 30241–30247.
54. Mohammed, M.M.D., Ibrahim, N.A., El-Sakhawy, F.S., Mohamed, K.M., Deabes, D.A.H., Two new cytotoxic furoquinoline alkaloids isolated from Aegle marmelos (Linn.) Correa. Nat. Prod. Res. 30 (2016), 2559–2566.
55. Nair, A.B., Jacob, S., A simple practice guide for dose conversion between animals and humans. J. Basic. Clin. Pharma 7 (2016), 27–31.
56. Navarro, V.J., Barnhart, H., Bonkovsky, H.L., Davern, T., Fontana, R.J., Grant, L., Reddy, K.R., Seeff, L.B., Serrano, J., Sherker, A.H., Stolz, A., Talwalkar, J., Vega, M., Vuppalanchi, R., Liver injury from herbals and dietary supplements in the US drug-induced liver injury Network. Hepatology 60 (2014), 1399–1408.
57. Navarro, V.J., Khan, I., Bjornsson, E., Seeff, L.B., Serrano, J., Hoofnagle, J.H., Liver Injury from herbal and dietary supplements. Hepatology 65 (2017), 363–373.
58. Ohta, A., Lukashev, D., Jackson, E.K., Fredholm, B.B., Sitkovsky, M., 1,3,7-trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J. Immunol. 179 (2007), 7431–7438.
59. Palming, J., Sjoholm, K., Jernas, M., Lystig, T.C., Gummesson, A., Romeo, S., Lonn, L., Carlsson, B., Carlsson, L.M.S., The expression of NAD(P)H: quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction. J. Clin. Endocr. Metab. 92 (2007), 2346–2352.
60. Patra, A., Mitra, A.K., Ghosh, A., Mukhopadhyay, P.K., Carbon-13 NMR spectra of tembamide, aegeline, and related amides. Org. Magn. Reson 16 (1981), 65–67.
61. Pyo, M.K., Lee, D.-H., Kim, D.-H., Lee, J.-H., Moon, J.-C., Chang, K.C., Yun-Choi, H.S., Enantioselective synthesis of (R)-(+)- and (S)-(-)-higenamine and their analogs with effects on platelet aggregation and experimental animal model of disseminated intravascular coagulation. Bioorg. Med. Chem. Lett. 18 (2008), 4110–4114.
62. Qin, S., Hou, D.-X., Multiple regulations of Keap1/Nrf2 system by dietary phytochemicals. Mol. Nutr. Food Res. 60 (2016), 1731–1755.
63. Roytman, M.M., Porzgen, P., Lee, C.L., Huddleston, L., Kuo, T.T., Bryant-Greenwood, P., Wong, L.L., Tsai, N., Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. Am. J. Gastroenterol. 109 (2014), 1296–1298.
64. Schilter, B., Andersson, C., Anton, R., Constable, A., Kleiner, J., O'Brien, J., Renwick, A.G., Korver, O., Smit, F., Walker, R., Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem. Toxicol. 41 (2003), 1625–1649.
65. Schneiderhan, W., Schmid-Kotsas, A., Zhao, J.S., Grunert, A., Nussler, A., Weidenbach, H., Menke, A., Schmid, R.M., Adler, G., Bachem, M.G., Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 34 (2001), 729–737.
66. Siegel, D., Ross, D., Immunodetection of NAD (P) H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic. Biol. Med. 29 (2000), 246–253.
67. Singh, R.P., Banerjee, S., Rao, A.R., Effect of Aegle marmelos on biotransformation enzyme systems and protection against free-radical-mediated damage in mice. J. Pharm. Pharmacol. 52 (2000), 991–1000.
68. Skibola, C.F., Smith, M.T., Potential health impacts of excessive flavonoid intake. Free Radic. Biol. Med. 29 (2000), 375–383.
69. Somanathan, R., Aguilar, H.R., Ventura, G.R., Smith, K.M., Syntheses of natural hydroxyamides using trimethylsilyl cyanide. Synth. Commun. 13 (1983), 273–280.
70. Starkey Lewis, P.J., Merz, M., Couttet, P., Grenet, O., Dear, J., Antoine, D.J., Goldring, C., Park, B.K., Moggs, J.G., Serum microRNA biomarkers for drug-induced liver injury. Clin. Pharmacol. Ther. 92 (2012), 291–293.
71. Stefanson, A.L., Bakovic, M., Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals. Nutrients 6 (2014), 3777–3801.
72. Stickel, F., Droz, S., Patsenker, E., Bogli-Stuber, K., Aebi, B., Leib, S.L., Severe hepatotoxicity following ingestion of Herbalife (R) nutritional supplements contaminated with Bacillus subtilis. J. Hepatol. 50 (2009), 111–117.
73. Strassburg, A., Strassburg, C.P., Manns, M.P., Tukey, R.H., Differential gene expression of NAD(P)H: quinone oxidoreductase and NRH: quinone oxidoreductase in human hepatocellular and biliary tissue. Mol. Pharmacol. 61 (2002), 320–325.
74. U.S. Food and Drug Administration, OxyElite Pro Supplements Recalled. Nov. 18, 2013 https://www.fda.gov/forconsumers/consumerupdates/ucm374742.htm. Accessed Date 25, May 2017.
75. U.S. Food and Drug Administration, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinicla Trials for Therapeutics in Adult Healthy Volunteers. 2005 http://www.fda.gov/cder/guidance/index.htm. Accessed Date 20, September 2016.
76. U.S. Food and Drug Administration, DMAA in Dietary Supplements. July 16, 2013, Food and Drug Administration https://www.fda.gov/food/dietarysupplements/productsingredients/ucm346576.htm. Accessed Date 7, October 2017.
77. Vargas, A.J., Burd, R., Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr. Rev. 68 (2010), 418–428.
78. Veerappan, A., Miyazaki, S., Kadarkaraisamy, M., Ranganathan, D., Acute and subacute toxicity studies of Aegle mamrelos Corr., an Indian medicinal plant. Phytomedicine 14 (2007), 209–215.
79. Waluga, M., Janusz, M., Karpel, E., Hartleb, M., Nowak, A., Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical impedance in obese women. Clin. Physiol. 18 (1998), 69–76.
80. Wang, J.-B., Zhao, H.-P., Zhao, Y.-L., Jin, C., Liu, D.-J., Kong, W.-J., Fang, F., Zhang, L., Wang, H.-J., Xiao, X.-H., Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L. in treating rat liver injury. PLoS One, 6, 2011, e24498.
81. Wojcikowski, K., Gobe, G., Animal studies on medicinal herbs: predictability, dose conversion and potential value. Phytother. Res. 28 (2014), 22–27.
82. Zhang, Y., Woods, R.M., Breitbach, Z.S., Armstrong, D.W., 1,3-dimethylamylamine (DMAA) in supplements and geranium products: natural or synthetic?. Drug. Test. Anal. 4 (2012), 986–990.
83. Zheng, X.C., Dai, W.C., Chen, X.H., Wang, K.Y., Zhang, W.Q., Liu, L., Hou, J.L., Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. J. Biomed. Sci., 22, 2015, 105.
84. Zoja, C., Corna, D., Nava, V., Locatelli, M., Abbate, M., Gaspari, F., Carrara, F., Sangalli, F., Remuzzi, G., Benigni, A., Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am. J. Physiol. Ren. Physiol. 304 (2013), F808–F819.